The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.
Quant Mid Cap Fund - Direct (G) 228.24 8,29,800 2.40 Quant Large and Mid Cap Fund - Direct (B) 62.16 2,26,000 1.62 Quant Large and Mid Cap Fund - Direct (IDCW) 62.16 2,26,000 1.62 Quant Large and Mid ...
Some results have been hidden because they may be inaccessible to you